The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation. The ...

Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also ...

People with HIV may have to take multiple medicines just to keep the virus under control. Medicines for HIV are usually taken every day, and it is crucial that people do not miss their dose or else ...

Cabenuva is administered as two separate injections into the gluteal muscle by a healthcare professional to treat HIV in adults and in children 12 years and older who weigh at least 77 pounds. The ...

(Reuters) - The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare. "This is the first ...

Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...

Cabenuva (cabotegravir/rilpivirine) is a prescription drug used to treat HIV in certain adults and children. Cabenuva comes as a liquid suspension (a type of liquid ...

Cabenuva, an injectable medication for HIV, may cause both mild and serious side effects. More common side effects include fever, headache, fatigue, nausea, and injection site reactions. Serious but ...

Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen at the GSK research centre in Stevenage (Reuters) - GlaxoSmithKline's HIV treatments division has received ...

Last week, the FDA denied the approval of Cabenuva, the first of its kind monthly HIV injection treatment. Developers hoped that the monthly injection would replace daily pills, thus making life ...

Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ...

A kit with two injectable medicines—ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— CABENUVA was co-developed as part of a collaboration with Janssen and builds on ViiV Healthcare’s industry ...